As of September 30, 2025, Janux reported cash and cash equivalents and short-term investments of $989.0 million, compared to $1.03 billion at December 31, 2024. “With enrollment ongoing in the JANX007 and JANX008 clinical trials and multiple new drug candidates expected to enter the clinic next year, we remain confident in our ability to advance these programs, supported by a strong balance sheet that enables continued execution,” said David Campbell, Ph.D., President and CEO of Janux.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JANX:
- Janux Therapeutics rumor highlighted in Betaville alert
- Janux Therapeutics Advances with Promising Study on JANX008 for Solid Tumor Treatment
- Janux Therapeutics Advances Prostate Cancer Study with JANX007
- BTIG biotech analyst holds an analyst/industry conference call
- Janux Therapeutics Announces Departure of Chief Strategy Officer